PMN — ProMIS Neurosciences Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1374339 ·
Last close
$3.21
Market Cap
$28.88M
52W High
$27.40
52W Low
$2.78
ADV30
296,385
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -12,266,399 | -11,729,656 | 56,693,933 | 53,429,280 | 7,294,999 |
| Mar 2026 | 0 | — | -8,644,895 | -8,244,372 | 67,411,571 | 63,814,345 | 6,693,999 |
| Dec 2025 | 0 | — | -10,772,119 | -10,674,088 | 9,182,421 | 6,116,556 | 10,441,013 |
| Sep 2025 | 0 | — | -11,750,432 | -11,580,126 | 21,458,147 | 15,399,165 | 12,270,792 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-42,106,116
Investing CF
—
Financing CF
$91,025,979
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-15.80
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-150,380,249
Inventory
—
Receivables
$215,226
ST Investments
$33,753
EBIT TTM
$-43,165,508
Pretax Income TTM
$-42,228,242
Interest Exp TTM
$0
Analysts
6
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -40,167,308 | -39,719,147 | 9,182,421 | 10,441,013 | -1,258,592 | -28,118,579 |
| Dec 2024 | 0 | -16,827,478 | 2,778,873 | 18,911,456 | 2,423,280 | 16,488,176 | -27,182,095 |
| Dec 2023 | 0 | -14,262,733 | -13,212,482 | 13,619,145 | 9,865,849 | 3,753,296 | -10,843,676 |
| Dec 2022 | 0 | -23,379,912 | -18,062,263 | 6,924,646 | 8,272,418 | -1,347,772 | -17,033,883 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$0
NetIncome TTM
$-42,228,243
OpCashFlow TTM
—
Assets (Latest)
$56,693,933
Forward EPS
$-4.04
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RDPTF | Radiopharm Theranostics Ltd | $28.89M | $0.01 | — |
| AYTU | AYTU BIOPHARMA, INC | $28.91M | $2.66 | — |
| SCYX | SCYNEXIS INC | $28.37M | $2.85 | — |
| PYRGF | PyroGenesis Canada Inc. | $28.34M | $0.13 | — |
| PRRUF | IMMUTEP Ltd | $29.47M | $0.02 | — |
News headlines (Yahoo Finance, 1h cache)
ProMIS Neurosciences Licenses Next-Generation TXP1 Brain-Selective Shuttling Technology from Ossianix to Expand PMN310 Franchise and Pipeline
2026-11-17 07:30 · Yahoo
ProMIS Neurosciences, Inc. Q3 2026 Earnings Call Summary
2026-11-13 13:30 · Yahoo
ProMIS Neurosciences Announces Third Quarter 2026 Financial Results and Reaffirms First Quarter 2027 Topline Data Timing
2026-11-12 21:05 · Yahoo
ProMIS Neurosciences to Participate in Upcoming Conferences in November
2026-11-05 12:00 · Yahoo
ProMIS Neurosciences to Report Third Quarter 2026 Financial Results and Business Update on November 12, 2026
2026-11-03 12:00 · Yahoo
Wall Street Analysts Believe Promis Neurosciences (PMN) Could Rally 292.95%: Here's is How to Trade
2026-10-29 12:55 · Yahoo
ProMIS Neurosciences to Participate in Upcoming Conferences and Events in September
2026-09-01 12:00 · Yahoo
ProMIS Neurosciences Inc (PMN) (Q2 2026) Earnings Call Highlights: Zero ARIA-E Cases and ...
2026-08-14 05:02 · Yahoo
Promis Neurosciences Q2 Earnings Call Highlights
2026-08-14 02:04 · Yahoo
ProMIS Neurosciences Announces Second Quarter 2026 Financial Results and Provides Corporate Highlights
2026-08-13 20:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.